Literature DB >> 24737677

Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis.

Yoon Young Choi1, Jung Min Bae, Ji Yeong An, In Gyu Kwon, In Cho, Hyun Beak Shin, Tanaka Eiji, Mohammad Aburahmah, Hyung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh.   

Abstract

BACKGROUND AND
OBJECTIVE: The relationship between survival in gastric cancer patients and the status of microsatellite instability (MSI) has not yet been established. The purpose of this meta-analysis was to obtain integrated and more precise data for the value of MSI as a prognostic marker in gastric cancer.
METHODS: A comprehensive systematic review and meta-analysis were conducted using major electronic databases (PubMed, EMBASE, and the Cochrane Central) with keywords related to "microsatellite instability," "gastric cancer," and "prognosis."
RESULTS: Twenty-four studies with 5,438 participants (712 cases were MSI gastric cancer) were included for pooling risk estimates of MSI in gastric cancer. Seventeen studies reported overall survival. The pooled hazard ratio (HR) for overall survival of MSI vs. non-MSI was 0.72 (95%CI: 0.59-0.88, P = .001) in a random-effects model. In the sensitivity analysis, the result from the most recent study showed the most heterogeneity.
CONCLUSION: MSI gastric cancer was associated with good prognosis but there was heterogeneity in the recent studies. Changed epidemiology and effects of chemotherapy are potential causes of heterogeneity. Establishing a consensus for defining MSI in gastric cancer should be preferred for future studies.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  MSI; gastric cancer; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24737677     DOI: 10.1002/jso.23618

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  44 in total

Review 1.  Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.

Authors:  Yu Sunakawa; Heinz-Josef Lenz
Journal:  Curr Treat Options Oncol       Date:  2015-04

Review 2.  Novel targets in the treatment of advanced gastric cancer: a perspective review.

Authors:  Elisa Fontana; Elizabeth C Smyth
Journal:  Ther Adv Med Oncol       Date:  2016-03       Impact factor: 8.168

3.  Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.

Authors:  Su-Jin Shin; Sang Yong Kim; Yoon Young Choi; Taeil Son; Jae-Ho Cheong; Woo Jin Hyung; Sung Hoon Noh; Chung-Gyu Park; Hyoung-Il Kim
Journal:  Oncologist       Date:  2019-03-20

Review 4.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

5.  Loss of ARID1A Expression in Gastric Cancer: Correlation with Mismatch Repair Deficiency and Clinicopathologic Features.

Authors:  Kyung-Ju Kim; Hae Yoen Jung; Mee-Hye Oh; Hyundeuk Cho; Ji-Hye Lee; Hyun Ju Lee; Si-Hyong Jang; Moon Soo Lee
Journal:  J Gastric Cancer       Date:  2015-09-30       Impact factor: 3.720

6.  Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.

Authors:  Daniel J McGrail; Jeannine Garnett; Jun Yin; Hui Dai; David J H Shih; Truong Nguyen Anh Lam; Yang Li; Chaoyang Sun; Yongsheng Li; Rosemarie Schmandt; Ji Yuan Wu; Limei Hu; Yulong Liang; Guang Peng; Eric Jonasch; David Menter; Melinda S Yates; Scott Kopetz; Karen H Lu; Russell Broaddus; Gordon B Mills; Nidhi Sahni; Shiaw-Yih Lin
Journal:  Cancer Cell       Date:  2020-02-27       Impact factor: 31.743

7.  Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.

Authors:  Chun-Yi Tsai; Tien-An Lin; Shih-Chiang Huang; Jun-Te Hsu; Chun-Nan Yeh; Tse-Ching Chen; Cheng-Tang Chiu; Jen-Shi Chen; Ta-Sen Yeh
Journal:  Oncologist       Date:  2020-02-14

8.  Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade.

Authors:  Dana M Roque; Alessandro D Santin
Journal:  Expert Rev Clin Immunol       Date:  2016-12-12       Impact factor: 4.473

Review 9.  Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.

Authors:  Ankur K Nagaraja; Osamu Kikuchi; Adam J Bass
Journal:  Cancer Discov       Date:  2019-11-14       Impact factor: 39.397

Review 10.  Molecular alterations in gastric cancer with special reference to the early-onset subtype.

Authors:  Małgorzata Skierucha; Anya Na Milne; G Johan A Offerhaus; Wojciech P Polkowski; Ryszard Maciejewski; Robert Sitarz
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.